NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANYOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.
Bionor Pharma ASA - Key information relating to the conditional Subsequent Offering
Oslo, 24 November 2016
Reference is made to Bionor Pharma ASA's ("Bionor" or the "Company") announcement regarding a successfully completed Private Placement and a contemplated fully underwritten Subsequent Offering published earlier today. The Private Placement and Subsequent Offering are conditional upon approval by the shareholders in an extraordinary general meeting (the "EGM") to be held on 14 December 2016.
The Board has proposed to conduct a Subsequent Offering to existing shareholders who were not allocated shares in the Private Placement nor participated in the underwriting consortium, provided that such shareholders are not resident in a jurisdiction where such offering would be unlawful, or would (in jurisdictions other than Norway) require any prospectus filing, registration or similar action. The Subsequent Offering is inter alia subject to approval by the EGM, completion of the Company's acquisition of Solon Eiendom AS and the Private Placement and a prospectus being approved by the Norwegian Financial Supervisory Authority and published by the Company.
Key information in relation to the conditional subsequent offering:
Date on which the terms and conditions of the rights offering were announced 21 November 2016
Last day including right 23 November 2016
Ex-date 24 November 2016
Record date 25 November 2016
Date of approval 14 December 2016
Maximum number of new shares in the subsequent offering 666,666,666 new shares
Subscription price NOK 0.15 per share
Shall the rights be listed yes/no Yes
This information is published in accordance with the requirements of the Continuing Obligations.
